News | May 13, 2021
Eris Lifesciences reports Q4FY21 consolidated net profit of Rs. 68.24 Cr
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
The facility is expected to be completed in 2024
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5% has an estimated market size of US $80 million for twelve months ending December 2020 according to IQVIA
The company reported total income of Rs.390.05 crores during the 12 months period ended March 31, 2021
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
The CDMO upgrade represents a transformational step for Remedium Lifecare
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
Subscribe To Our Newsletter & Stay Updated
